Ipca Labs hopes to continue doing very well in H2FY14 especially in its India formulation business, says ED AK Jain. It is awating USFDA approvals for Indore SEZ which, the company feels will boost its business going forward.
first published: Oct 25, 2013 11:56 am
A collection of the most-viewed Moneycontrol videos.

Live: Positive start to November series, Nifty sustains above 26,000 | Closing Bell

Live: Will Nifty continue to chase 26,000? | Opening Bell

Stock Market LIVE: Sensex, Nifty Off Day’s Lows | F&O Expiry Sparks Volatility | Closing Bell

‘Ashoka University Won’t Expand to Other Cities’ | Pramath Raj Sinha & Ashish Dhawan LIVE
You are already a Moneycontrol Pro user.

